Advemto is developing barcoded consumable cartridges that address a growing bottleneck in drug discovery: AI can generate candidates much faster than they can be experimentally tested. Its technology links what individual cells do with their identity at million-scale, enabling substantially more designs to be screened through a workflow compatible with common laboratory instruments.

The platform targets a US$5B preclinical antibody discovery market within a US$25B broader preclinical discovery opportunity. Optical decoding has been demonstrated, four patents filed, and biopharma pilots are targeted for 2027.

The team is led by CEO and Founder Dr Justin Hodgkiss and CTO Dr Alex Barker, supported by a board with life-sciences experience.

Advemto is raising NZ$5M for pilot manufacturing, technical proof points and its biopharma Early Access Program.

Advemto is a EA Fund 4 portfolio company. Read investor notes